HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin.

Abstract
The in vivo anti-Candida activities of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991 (cilofungin), L-687,901 (tetrahydroechinocandin B), and L-687,781 (a papulacandin analog) were evaluated by utilizing a murine model of disseminated candidiasis that has enhanced susceptibility to Candida albicans but increased sensitivity for discriminating antifungal efficacy. DBA/2 mice were challenged intravenously with 1 x 10(4) to 5 x 10(4) CFU of C. albicans MY1055 per mouse. Compounds were administered intraperitoneally at concentrations ranging from 1.25 to 10 mg/kg of body weight twice daily for 4 days. At 6 h and 1, 2, 3, 4, 7, and 9 days after challenge, five mice per group were sacrificed and their kidneys were homogenized and plated for enumeration of Candida organisms (CFU per gram). Progressiveness of response trends and no-statistical-significance-of-trend doses were derived to rank compound efficacy. 1,3-beta-D-Glucan synthesis 50% inhibitory concentrations were determined by using a C. albicans (MY1208) membrane glucan assay. Candida and Cryptococcus neoformans MICs and minimal fungicidal concentrations were determined by broth microdilution. L-671,329, L-646,991, L-687,901, and L-687,781 showed similar 1,3-beta-D-glucan activities, with 50% inhibitory concentrations of 0.64, 1.30, 0.85, and 0.16 micrograms/ml, respectively. Data from in vitro antifungal susceptibility studies showed that L-671,329, L-646,991, and L-687,901 had similar MICs ranging from 0.5 to 1.0 micrograms/ml, while L-687,781 showed slightly higher MICs of 1.0 to 2.0 micrograms/ml for C. albicans MY1055. Lipopeptide compounds were ineffective against C. neoformans strains. Results from in vivo experiments comparing significant trend and progressiveness in response analyses indicated that L-671,329 and L-646,991 were equipotent but slightly less active than L-687-901, while L-687,781 was ineffective at 10 mg/kg. Fungicidal activities of L-671,329, L-646,991, and L-687,901 were observed in vivo, with significant reduction in Candida CFU per gram of kidneys compared with those in sham-treated mice at doses of > or = 2.5 mg/kg evident as early as 1 day after challenge.
AuthorsK Bartizal, G Abruzzo, C Trainor, D Krupa, K Nollstadt, D Schmatz, R Schwartz, M Hammond, J Balkovec, F Vanmiddlesworth
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 36 Issue 8 Pg. 1648-57 (Aug 1992) ISSN: 0066-4804 [Print] United States
PMID1416847 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Anti-Bacterial Agents
  • Antifungal Agents
  • Azoles
  • Echinocandins
  • Glucans
  • Peptides
  • Peptides, Cyclic
  • Pyrans
  • beta-Glucans
  • pneumocandin A(0)
  • L 687781
  • tetrahydroechinocandin B
  • cilofungin
  • beta-1,3-glucan
Topics
  • Animals
  • Anti-Bacterial Agents
  • Antifungal Agents (pharmacology, therapeutic use)
  • Azoles (therapeutic use)
  • Candida albicans (drug effects, metabolism)
  • Candidiasis (drug therapy, microbiology)
  • Echinocandins
  • Glucans (biosynthesis)
  • Kidney (microbiology)
  • Lethal Dose 50
  • Mice
  • Mice, Inbred DBA
  • Microbial Sensitivity Tests
  • Peptides
  • Peptides, Cyclic (pharmacology, therapeutic use)
  • Pyrans (pharmacology, therapeutic use)
  • beta-Glucans

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: